Michael B. Jordan, MD
- Professor, UC Department of Pediatrics
- michael.jordan@cchmc.org
- Board Certified
About
MD: UT Southwestern, Dallas, TX, 1993.
Residency: Children's Hospital of Dallas, Dallas, TX, 1996.
Fellowship: The Children's Hospital, Denver, CO, 2002.
Certification: American Board of Pediatrics, 1996; Sub-board of Pediatric Heme/Onc, 2002.
Interests
Histiocytic disorders: HLH and LCH
Services and Specialties
Cancer and Blood Diseases, Immune Deficiencies and Histiocytosis, Bone Marrow Transplantation BMT, Leukemia, Hemophagocytic lymphohistiocytosisHLH, Histiocytosis Center, Autoimmune Liver Disease, Rare Lung Diseases
Interests
Better understanding histiocytic disorders and developing novel therapies for them; regulation of the immune response; immunotherapy of cancer
Research Areas
Bone Marrow Transplantation and Immune Deficiency, Cancer and Blood Diseases, Immunobiology
Insurance Information
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Publications
Prospective two center study of CD38 bright CD8+ effector memory T-cells as a predictor of acute GVHD. Transplantation Reports. 2022; 7.
Quercetin ameliorates XIAP deficiency-associated hyperinflammation. Blood. 2022; 140:706-715.
HLH: birds of a feather flock together. Blood. 2022; 140:167-168.
P1203: THE OPTIMIZED HLH INFLAMMATORY (OHI) INDEX IDENTIFIES LYMPHOMA PATIENTS WITH UNEXPECTEDLY HIGH MORTALITY NOT RELATED TO DISEASE PROGRESSION. HemaSphere. 2022; 6:1089-1090.
Consensus-Based Guidelines for the Recognition, Diagnosis, and Management of Hemophagocytic Lymphohistiocytosis in Critically Ill Children and Adults. Critical Care Medicine. 2022; 50:860-872.
Emapalumab in primary haemophagocytic lymphohistiocytosis and the pathogenic role of interferon gamma: A pharmacometric model-based approach. British Journal of Clinical Pharmacology. 2022; 88:2128-2139.
A Case of Chronic Lymphocytic Leukemia Complicated by Hemophagocytic Lymphohistiocytosis: Identifying the Aberrant Immune Response. Journal of General Internal Medicine. 2022; 37:1542-1546.
Malignancy-associated haemophagocytic lymphohistiocytosis. The Lancet Haematology. 2022; 9:e217-e227.
An improved index for diagnosis and mortality prediction in malignancy-associated hemophagocytic lymphohistiocytosis. Blood. 2022; 139:1098-1110.
High risk of relapsed disease in patients with NK/T-cell chronic active Epstein-Barr virus disease outside of Asia. Blood Advances. 2022; 6:452-459.
From the Blog
Clinical Trial Success Caps Long Journey for HLH Treatment
Michael B. Jordan, MD, Alexei A. Grom, MD3/22/2021
NEJM: Emapalumab Clinical Trial Shows Positive Results Against HLH
Michael B. Jordan, MD5/7/2020
Breakthrough Therapy Improves Life for Children with LRBA Deficiency
Michael B. Jordan, MD6/28/2019
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2022 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey